CD8A and neoplasm: Biomarkers predictive of the immunotherapeutic effects of ICIs have been extensively studied and discussed, with their predictive efficacy thought to depend on tumor antigenicity and antigen-presentation efficiency as measured by APS, IIS, TIS, CD8, IFNγ, IFNγ.GS, PDL1, TIDE [14], and APS7 [15].